April 30, 2014 / 12:35 PM / 3 years ago

Teva's abuse-resistant painkiller succeeds in study

April 30 (Reuters) - Israel's Teva Pharmaceutical Industries Ltd said its experimental abuse-resistant pain drug significantly reduced patients' chronic low back pain in a late-stage trial.

The drug is a twice-daily formulation of hydrocodone, which belongs to a powerful class of painkillers known as opioids that are also frequently abused.

Teva is developing the drug, called CEP-33237, for managing pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are not enough.

Teva said it expected to submit a U.S. marketing application for the drug by the end of 2014. (Reporting by Esha Dey in Bangalore)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below